Bioatla to announce fourth quarter and full-year 2024 financial results and provide business highlights on march 27, 2025

San diego, march 19, 2025 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on thursday, march 27, 2025 at 4:30 p.m. et to discuss its financial results for the fourth quarter and full-year ended december 31, 2024 and provide business highlights.
BCAB Ratings Summary
BCAB Quant Ranking